NCT04293419 - Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 18, 2019

Primary Completion Date

December 18, 2024

Study Completion Date

March 1, 2025

Conditions

Rectal Cancer

Interventions

DRUG

Durvalumab (MEDI4736)

6 cycles of mFOLFOX6 (oxaliplatin, leucovorin and fluorouracil) followed by long course chemoradiotherapy (50.4 Gy together with capecitabine) followed by surgery. Patients will receive durvalumab 1500 mg every 4 weeks during induction chemotherapy, chemoradiotherapy and waiting period until surgery.

Trial Locations (10)

15006

NOT_YET_RECRUITING

Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña

28041

NOT_YET_RECRUITING

H. 12 de Octubre, Madrid

46009

NOT_YET_RECRUITING

Instituto Valenciano de Oncología (IVO), Valencia

50009

NOT_YET_RECRUITING

H. Miguel Servet Zaragoza, Zaragoza

Unknown

RECRUITING

Parc Taulí, Sabadell

NOT_YET_RECRUITING

H. Navarra, Pamplona

NOT_YET_RECRUITING

H. de Elche, Elche

08970

NOT_YET_RECRUITING

H. Moises Broggi, Sant Joan Despí

08035

RECRUITING

Hospital Vall d'Hebron, Barcelona

08036

RECRUITING

H. Clínic Barcelona, Barcelona